Campbell & CO Investment Adviser LLC Invests $1.17 Million in Thermo Fisher Scientific Inc. $TMO

Campbell & CO Investment Adviser LLC acquired a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO) in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 2,892 shares of the medical research company’s stock, valued at approximately $1,173,000.

Several other institutional investors also recently modified their holdings of TMO. Connor Clark & Lunn Investment Management Ltd. boosted its stake in Thermo Fisher Scientific by 721.5% during the 2nd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 62,821 shares of the medical research company’s stock worth $25,471,000 after acquiring an additional 55,174 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. boosted its position in shares of Thermo Fisher Scientific by 29.5% during the second quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,257,424 shares of the medical research company’s stock worth $915,295,000 after purchasing an additional 514,399 shares in the last quarter. Magellan Asset Management Ltd grew its holdings in shares of Thermo Fisher Scientific by 115.7% in the 2nd quarter. Magellan Asset Management Ltd now owns 12,449 shares of the medical research company’s stock valued at $5,048,000 after buying an additional 6,678 shares during the period. Aviva PLC raised its stake in Thermo Fisher Scientific by 58.9% during the 2nd quarter. Aviva PLC now owns 426,102 shares of the medical research company’s stock worth $172,767,000 after buying an additional 157,889 shares during the period. Finally, Prospera Financial Services Inc lifted its holdings in Thermo Fisher Scientific by 128.0% during the second quarter. Prospera Financial Services Inc now owns 19,441 shares of the medical research company’s stock worth $7,884,000 after acquiring an additional 10,913 shares in the last quarter. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, CEO Marc N. Casper sold 17,104 shares of the business’s stock in a transaction on Friday, October 24th. The shares were sold at an average price of $573.54, for a total transaction of $9,809,828.16. Following the transaction, the chief executive officer directly owned 113,762 shares in the company, valued at approximately $65,247,057.48. The trade was a 13.07% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Lisa P. Britt sold 10,225 shares of the stock in a transaction on Friday, November 7th. The shares were sold at an average price of $571.62, for a total transaction of $5,844,814.50. Following the completion of the sale, the vice president owned 14,145 shares of the company’s stock, valued at approximately $8,085,564.90. This represents a 41.96% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 46,645 shares of company stock valued at $25,825,699 over the last three months. Corporate insiders own 0.33% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on TMO. Evercore ISI raised their price target on Thermo Fisher Scientific from $525.00 to $590.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 7th. JPMorgan Chase & Co. raised their target price on shares of Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock an “overweight” rating in a report on Thursday, October 9th. William Blair assumed coverage on shares of Thermo Fisher Scientific in a research report on Monday, August 18th. They set an “outperform” rating for the company. Morgan Stanley boosted their price objective on shares of Thermo Fisher Scientific from $560.00 to $656.00 and gave the company an “overweight” rating in a research report on Tuesday, October 28th. Finally, Argus increased their target price on Thermo Fisher Scientific from $580.00 to $610.00 and gave the stock a “buy” rating in a report on Wednesday, October 29th. Nineteen research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $601.65.

Thermo Fisher Scientific Stock Up 0.3%

Thermo Fisher Scientific stock opened at $588.53 on Thursday. The company has a fifty day simple moving average of $524.35 and a 200 day simple moving average of $465.87. The company has a current ratio of 1.50, a quick ratio of 1.11 and a debt-to-equity ratio of 0.62. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $610.97. The company has a market cap of $221.12 billion, a P/E ratio of 34.00, a price-to-earnings-growth ratio of 3.27 and a beta of 0.82.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share for the quarter, beating the consensus estimate of $5.50 by $0.29. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%.The company had revenue of $11.12 billion during the quarter, compared to analysts’ expectations of $10.90 billion. During the same quarter last year, the company earned $5.28 EPS. Thermo Fisher Scientific’s revenue for the quarter was up 4.9% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. Research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific announced that its board has initiated a stock repurchase plan on Thursday, November 6th that allows the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization allows the medical research company to reacquire up to 2.4% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s leadership believes its shares are undervalued.

Thermo Fisher Scientific Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, January 15th. Stockholders of record on Monday, December 15th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 0.3%. The ex-dividend date of this dividend is Monday, December 15th. Thermo Fisher Scientific’s dividend payout ratio is presently 9.94%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.